BridgeMD
New treatment option for Cataract
Official title Evaluation of Visual Outcomes, Complications, and Neuroadaptation Following Bilateral Implantation of enVista Envy Trifocal Intraocular Lenses
ClinicalTrials.gov ID: NCT07696130
What this study is testing
- What it's testing
- The enVista Envy intraocular lens (IOL) manufactured by Bausch + Lomb is a new multifocal intraocular lens based on diffractive optics. It was registered with the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in September 2025.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 75
You may be able to join if
- Bilateral cataract or refractive lens exchange candidates.
- Presbyopia and/or hyperopia.
- Preoperative corneal astigmatism less than 1.00 diopter (D).
- Absence of ocular diseases other than cataract.
- High motivation to achieve spectacle independence.
You likely can't join if
- Ocular Conditions:
- Glaucoma.
- Amblyopia.
- Macular diseases (including macular degeneration and other macular pathology).
- Angle kappa greater than 0.5 mm.
- Dry eye disease.
See the full eligibility criteria
- Bilateral cataract or refractive lens exchange candidates.
- Presbyopia and/or hyperopia.
- Preoperative corneal astigmatism less than 1.00 diopter (D).
- Absence of ocular diseases other than cataract.
- High motivation to achieve spectacle independence.
- Patients willing to accept the possibility of mild photic phenomena, such as glare and halos.
- Ocular Conditions:
- Glaucoma.
- Amblyopia.
- Macular diseases (including macular degeneration and other macular pathology).
- Angle kappa greater than 0.5 mm.
- Dry eye disease.
- Corneal disorders.
- Pupil abnormalities.
- Irregular astigmatism.
- Ocular motility disorders or strabismus.
- Pupil diameter \ 6.0 mm under mesopic conditions.
- Abnormalities of the capsular bag or zonular apparatus, including pseudoexfoliation syndrome (PEX).
- Lifestyle Factors:
- Patients with unrealistic expectations regarding postoperative visual outcomes.
- Individuals whose professions require highly precise visual performance, such as pilots, professional drivers, architects, or similar occupations.
- Patients satisfied with using spectacles for near vision.
- Age greater than 75 years (due to potential difficulties with neuroadaptation to new visual conditions).
- Psychological and Personality Factors:
- Patients with psychiatric disorders that may interfere with study participation or outcome assessment.
- Patients dissatisfied with progressive addition lenses (progressive spectacles).
- Patients with dyslexia or a history of stroke.
- Type A personality traits (perfectionists).
- Patients will also be excluded if the calculated IOL power falls outside the available range of +6.00 D to +34.00 D or if they have a history of laser vision correction surgery.
The study team makes the final eligibility decision.
Where it's taking place
- Szczecin, Zachodnipomorskie, Poland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Szczecin, Zachodnipomorskie, Poland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.